Results 141 to 150 of about 58,717 (264)

Scleral thickness in patients with obstructive sleep apnea syndrome. [PDF]

open access: yesJpn J Ophthalmol
Akgun Z   +4 more
europepmc   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton   +9 more
wiley   +1 more source

Evaluation of Oral Appliance Therapy in Patients with Obstructive Sleep Apnea Syndrome: A Comparative Analysis by Age, Severity, and BMI. [PDF]

open access: yesYonago Acta Med
Kawasaki M   +8 more
europepmc   +1 more source

The problem of obstructive sleep apnea syndrome in asthmatic patients

open access: diamond, 2017
E. G. Sheludko   +3 more
openalex   +1 more source

ANGPTL8 is upregulated in subcutaneous adipose tissue at early term after bariatric surgery in patients living with obesity

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
Bariatric surgery induces early immunological and transcriptomic modulations in subcutaneous adipose tissue, suggesting a transient pro‐inflammatory state and tissue remodeling process in patients living with obesity. ANGPTL8 could play a role in improving metabolic homeostasis at early‐term after bariatric surgery offering new insights into adipose ...
Ester Martínez Negro   +14 more
wiley   +1 more source

Obstructive sleep apnea syndrome in children with cerebral palsy in Brazil: a multicenter study. [PDF]

open access: yesJ Pediatr (Rio J)
Dias BLS   +9 more
europepmc   +1 more source

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli   +58 more
wiley   +1 more source

Home - About - Disclaimer - Privacy